GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (LTS:0H8T) » Definitions » Float Percentage Of Total Shares Outstanding

Aclaris Therapeutics (LTS:0H8T) Float Percentage Of Total Shares Outstanding : 83.93% (As of May. 14, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Aclaris Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aclaris Therapeutics's float shares is 90.88 Mil. Aclaris Therapeutics's total shares outstanding is 108.28 Mil. Aclaris Therapeutics's float percentage of total shares outstanding is 83.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aclaris Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aclaris Therapeutics's Institutional Ownership is 8.65%.

Aclaris Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aclaris Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=90.88/108.28
=83.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (LTS:0H8T) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
LDDD XGN OCX MDXH BDSX FONR NOTV PRE ADVB MEHCQ TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
ACRS:USA 8AT:Germany
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Website
https://www.aclaristx.com
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines